BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang K, Jiang K, Xu Z, Song Y, Wang J. Targeting sphingosine kinase 1 for the treatment of pulmonary arterial hypertension. Future Medicinal Chemistry 2019;11:2939-53. [DOI: 10.4155/fmc-2019-0130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Vastrad B, Vastrad C. Bioinformatics Analysis of next generation sequencing data for Risk Prediction in Patients with Type 1 diabetes mellitus.. [DOI: 10.1101/2022.03.17.484749] [Reference Citation Analysis]
2 Bu Y, Wu H, Deng R, Wang Y. Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases. Front Pharmacol 2021;12:733387. [PMID: 34737701 DOI: 10.3389/fphar.2021.733387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
3 Ji Y, Lisabeth EM, Neubig RR. Transforming Growth Factor β1 Increases Expression of Contractile Genes in Human Pulmonary Arterial Smooth Muscle Cells by Potentiating Sphingosine-1-Phosphate Signaling. Mol Pharmacol 2021;100:53-60. [PMID: 34031187 DOI: 10.1124/molpharm.120.000019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Dhangadamajhi G, Singh S. Malaria link of hypertension: a hidden syndicate of angiotensin II, bradykinin and sphingosine 1-phosphate. Hum Cell 2021;34:734-44. [PMID: 33683655 DOI: 10.1007/s13577-021-00513-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]